摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(bromomethyl)-2-methylcyclopropane | 31950-58-0

中文名称
——
中文别名
——
英文名称
1-(bromomethyl)-2-methylcyclopropane
英文别名
(E)-2-methylcyclopropylmethyl bromide
1-(bromomethyl)-2-methylcyclopropane化学式
CAS
31950-58-0
化学式
C5H9Br
mdl
MFCD16860577
分子量
149.03
InChiKey
XOXUXLDFDIJSPF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    102.7±8.0 °C(Predicted)
  • 密度:
    1.386±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    6
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE-1-OXYDE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU FACTEUR XIA
    申请人:MERCK SHARP & DOHME
    公开号:WO2018039094A1
    公开(公告)日:2018-03-01
    The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    本发明提供了一种化合物(I)及包含一种或多种所述化合物的药物组合物,以及使用所述化合物治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。这些化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽原的双重抑制剂。
  • [EN] (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE (PIPÉRIDIN-3-YL)(NAPHTALÉN-2-YL)MÉTHANONE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME INHIBITEURS DE L'HISTONE DÉMÉTHYLASE KDM2B POUR LE TRAITEMENT DU CANCER
    申请人:GENENTECH INC
    公开号:WO2016112284A1
    公开(公告)日:2016-07-14
    The present invention relates to (piperidin-3-yl)(naphthalen-2-yl) methanone derivatives and related compounds as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and discloses methods of using said compositions in the treatment of cancer, such as lung cancer, leukemia or lymphoma.
    本发明涉及(哌啶-3-基)(萘-2-基)甲酮衍生物和相关化合物,作为一种或多种组蛋白去甲基酶抑制剂,如KDM2b。该发明还提供了包括本发明化合物的药学上可接受的组合物,并公开了使用该类组合物治疗癌症,如肺癌、白血病或淋巴瘤的方法。
  • [EN] ASPARTYL PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ASPARTYL-PROTEASE
    申请人:SUNESIS PHARMACEUTICALS INC
    公开号:WO2003106405A1
    公开(公告)日:2003-12-24
    The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.
    本发明提供具有以下结构的化合物(I):其中R'、R0、R1、X1、R2、R3、R3'、X2、X3和R4如本文所定义,并且其药物组合物。本发明还提供抑制蛋白酶的方法,更具体地是天冬氨酸蛋白酶。在某些实施例中,这些化合物抑制BACE(β-APP裂解酶),因此可用于治疗或预防大脑中存在β-淀粉样沉积的疾病(包括但不限于阿尔茨海默病)。本发明还提供了制备本发明化合物的方法。
  • Optically active pyrrolopyridazine derivatives
    申请人:SANKYO COMPANY, LIMITED
    公开号:US20020156079A1
    公开(公告)日:2002-10-24
    An optically active pyrrolopyridazine compound of the formula (I) or a pharmaceutically acceptable salt thereof: 1 wherein R 1 is alkyl; R 2 and R 3 are each independently alkyl; R 4 is optionally substituted aryl; and A is imino, oxygen or sulfur. The pyrrolopyridazine compound or pharmaceutically acceptable salts thereof of the present invention exhibit excellent gastric acid secretory inhibition activity and gastric mucous membrane protection activity, as well as excellent antibacterial activity against Helicobacter pylori. They are useful medicines and are particularly useful for treating or preventing ulcerative diseases.
    式(I)的旋光异构的吡咯吡啶嗪化合物或其药学上可接受的盐: 其中R1是烷基;R2和R3各自独立地是烷基;R4是可选取代的芳基;A是亚胺基、氧原子或硫原子。本发明的吡咯吡啶嗪化合物或其药学上可接受的盐,表现出优异的胃酸分泌抑制活性和胃粘膜保护活性,以及对幽门螺杆菌的优异抗菌活性。它们是有用的药物,特别是用于治疗或预防溃疡性疾病。
  • Pyrrolopyridazine compounds
    申请人:SANKYO COMPANY, LIMITED
    公开号:US20040014762A1
    公开(公告)日:2004-01-22
    A pyrrolopyridazine compound having the formula (I) or a pharmaceutically acceptable salt thereof: 1 wherein, R 1 is a C 2 -C 6 alkenyl group, a halogeno C 2 -C 6 alkenyl group, a C 3 -C 7 cycloalkyl group which may be optionally substituted or a C 3 -C 7 cycloalkyl- C 1 -C 6 alkyl group which may be optionally substituted. R 2 is a C 1 -C 6 alkyl group. R 3 is a hydroxymethyl group, a C 2 -C 6 aliphatic acyloxymethyl group, a C 6 -C 10 arylcarbonyloxymethyl group which may be optionally substituted, a C 1 -C 6 alkoxycarbonyloxymethyl group, a formyl group, a carboxyl group, a C 1 -C 6 alkoxycarbonyl group or a C 6 -C 10 aryloxycarbonyl group which may be optionally substituted. R 4 is a C 6 -C 10 aryl group which may be optionally substituted. A is an imino group, an oxygen atom or a sulfur atom. These compounds exhibit excellent gastric acid secretory inhibition activity and gastric mucous membrane protection activity etc. They are useful for prevention or treatment of ulcerative diseases and for Helicobacter pylori infections.
    一种具有以下式(I)或其药学上可接受的盐的吡咯吡啶化合物: 1其中,R1是C2-C6烯丙基,卤代C2-C6烯丙基,C3-C7环烷基,其可以选择性地取代或C3-C7环烷基-C1-C6烷基,其可以选择性地取代。R2是C1-C6烷基。R3是羟甲基,C2-C6脂肪酰氧甲基,C6-C10芳基羰基氧甲基,其可以选择性地取代,C1-C6烷氧羰基氧甲基,甲酰基,羧基,C1-C6烷氧羰基或C6-C10芳氧羰基,其可以选择性地取代。R4是C6-C10芳基,其可以选择性地取代。A是亚胺基,氧原子或硫原子。这些化合物表现出优异的胃酸分泌抑制活性和胃黏膜保护活性等。它们对于预防或治疗溃疡性疾病和幽门螺杆菌感染非常有用。
查看更多